Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Targeted nanohorns for lithium neutron capture therapy

Project description

Filled nanohorns deliver lithium for high-precision neutron capture therapy

The destructive effects of radiation therapy on healthy cells remains a challenge in cancer treatment. Neutron capture therapy (NCT) has the potential to reduce this damage. NCT harnesses isotopes that, when irradiated with neutrons, produce lethal particles with very short path lengths, limiting the destructive effects of radiotherapy to a single cell. The trick has been delivering enough neutron-active atoms to the tumour for effective therapy. The ERC-funded TARLIT project will design "nanohorn" carriers of enriched lithium compounds to deliver lithium nuclides into cancer cells. Given the production of higher energetic particles than those produced by currently available state-of-the-art systems, the use of lithium is expected to significantly improve the efficiency of NCT.

Objective

Cancer accounted for nearly 10 million deaths in 2020. Half of all cancer patients are treated with radiation therapy, either alone or combined with other therapeutic modalities (mainly surgery and chemotherapy). One of the first concerns related to radiotherapy is the toxicity of healthy organs and tissues close to the tumour. It is well-known that radiation therapy not only kills cancerous cells that divide, but also affects to the cells in division in healthy tissue. Neutron capture therapy (NCT) is a form of radiotherapy that exploits the potential of some specific isotopes for cancer treatment. The nuclear reaction that takes place when some isotopes are irradiated with neutrons, produces lethal particles with path lengths that can limit the destructive effects to a single cell, thus conferring high therapeutic precision to this form of radiotherapy. For this therapy to be successful, enough neutron active atoms must be delivered to the tumour site so a lethal capture reaction can take place. However, current benchmark pharmacologic agents are limited in their performance due to the low concentration of active species delivered in the tumour sites. TARLIT goes beyond the state-of-the-art and presents an innovative approach that consists on the design of nanoparticles as carriers of enriched lithium compounds. The possibility to deliver lithium nuclides into cancer cells, and the fact that nuclear reactions of lithium resultant from neutron irradiation produce higher energetic particles that the current state of the art, can significantly improve the efficiency of NCT in the eradication of cancer cells and tumours.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-POC2

See all projects funded under this call

Host institution

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Net EU contribution
€ 150 000,00
Address
CALLE SERRANO 117
28006 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)